EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Factors Influencing Nerinetide Effect on Clinical Outcome in Patients Without Alteplase Treatment in the ESCAPE-NA1 Trial

Mayank Goyal, Bijoy K Menon, Johanna Ospel, Mohammed Almekhlafi, Charlotte Zerna, Raul Nogueira, Ryan McTaggart, Andrew M Demchuk, Alexandre Y Poppe, Brian Buck, Kathy Heard, Manish Joshi und 18 weitere

Journal of Stroke · 31.01.2025 · 27 (1) · 95-101

DOI: 10.5853/jos.2024.03139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Stroke, erschienen am 31.01.2025. Verfasst von Mayank Goyal und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Imaging, Cumming School of Medicine, University of Calgary, Calgary, Canada. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institute of Health Research, Alberta Innovates, NoNO Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose In the ESCAPE-NA1 (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischaemic Stroke) trial, treatment with nerinetide was associated with improved outcomes in patients who did not receive intravenous alteplase. We compared the effect of nerinetide on clinical outcomes in patients without concurrent intravenous alteplase treatment within different patient subgroups.

Methods

ESCAPE-NA1 was a multicenter randomized trial in which acute stroke patients with baseline Alberta Stroke Program Early CT Score (ASPECTS) >4 undergoing endovascular treatment (EVT) were randomized to intravenous nerinetide or placebo. The primary outcome was independence (modified Rankin Scale [mRS] score 0–2) at 90 days. We assessed baseline, clinical, and imaging variables as predictors of outcome and for evidence of treatment effect modification. We constructed two multivariable models using variables known prior to randomization and variables known immediately post-EVT procedure to provide adjusted estimates of effect. We assessed for evidence of treatment effect modification using multiplicative interaction terms within each model.

Results

Four hundred forty-six patients were included in the analysis. Clinical outcomes were better in patients randomized to the nerinetide arm (mRS 0–2: 59.4% vs. 49.8%). There was possible treatment effect modification by ASPECTS score; patients with ASPECTS 8–10 showed a larger treatment effect compared to those with lower ASPECTS score. Younger age, lower NIHSS score, lower baseline serum glucose, absence of atrial fibrillation at baseline, higher ASPECTS score, middle cerebral artery (vs. internal carotid artery) occlusion, use of conscious or no sedation (vs. general anesthesia), and faster treatment were all predictors of favorable outcome.

Conclusion

Patients in the nerinetide arm who were not treated with concurrent alteplase showed improved clinical outcomes and the treatment effect was larger among patients with favorable ASPECTS profiles.

Schlagwörter

Stichwörter der Autor:innen

Acute ischemic strokeCerebroprotectionNerinetideNeuroprotectionThrombectomy

Autor:innen und Institutionen

  • Department of Diagnostic Imaging, Cumming School of Medicine, University of Calgary, Calgary, Canada.
  • Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.
  • Städtisches Klinikum Dresden, Dresden, Germany.
  • Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Warren Alpert School of Medicine, Brown University, Providence, RI, USA.
  • Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Förderung

  • Canadian Institute of Health Research
  • Alberta Innovates
  • NoNO Inc

Zitieren

APA

Goyal, M., Menon, B. K., Ospel, J., Almekhlafi, M., Zerna, C., Nogueira, R., McTaggart, R., Demchuk, A. M., Poppe, A. Y., Buck, B., Heard, K., Joshi, M., Haussen, D., Cutting, S., Coutts, S. B., Roy, D., Rempel, J. L., Field, T. S., Dowlatshahi, D., …, & ESCAPE-NA1 Investigators (2025). Factors Influencing Nerinetide Effect on Clinical Outcome in Patients Without Alteplase Treatment in the ESCAPE-NA1 Trial. Journal of Stroke, 27(1), 95-101. https://doi.org/10.5853/jos.2024.03139

Vancouver

Goyal M, Menon BK, Ospel J, Almekhlafi M, Zerna C, Nogueira R, et al. Factors Influencing Nerinetide Effect on Clinical Outcome in Patients Without Alteplase Treatment in the ESCAPE-NA1 Trial. Journal of Stroke. 2025;27(1):95-101. doi:10.5853/jos.2024.03139

BibTeX
@article{Goyal2025,
  author = {Goyal, Mayank and Menon, Bijoy K and Ospel, Johanna and Almekhlafi, Mohammed and Zerna, Charlotte and Nogueira, Raul and McTaggart, Ryan and Demchuk, Andrew M and Poppe, Alexandre Y and Buck, Brian and Heard, Kathy and Joshi, Manish and Haussen, Diogo and Cutting, Shawna and Coutts, Shelagh B and Roy, Daniel and Rempel, Jeremy L and Field, Thalia S and Dowlatshahi, Dar and Adel, Brian van and Swartz, Richard and Shah, Ruchir and Sauvageau, Eric and Puetz, Volker and Silver, Frank L and Campbell, Bruce and Chapot, René and Tymianski, Michael and Hill, Michael D and ESCAPE-NA1 Investigators, ESCAPE-NA1 Investigators},
  title = {Factors Influencing Nerinetide Effect on Clinical Outcome in Patients Without Alteplase Treatment in the ESCAPE-NA1 Trial},
  journal = {Journal of Stroke},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {95--101},
  doi = {10.5853/jos.2024.03139}
}
Kostenlos starten →